Trial Profile
A Phase 1, Open-label Study To Assess The Effects Of Talazoparib On Cardiac Repolarization In Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2019
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Medivation; Pfizer
- 14 Dec 2019 Results (n=494) of pooled analysis of five trials (EMBRACA, NCT01945775; ABRAZO, NCT02034916; NCT01286987, NCT03042910 & NCT02921919) assessing safety of talazoparib in patients with avanced breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium.
- 18 Aug 2017 Status changed from recruiting to completed.
- 06 Feb 2017 New trial record